OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis
Leiming Wang, Xi Yang, Fei Zhou, et al.
Bioengineered (2022) Vol. 13, Iss. 3, pp. 7197-7208
Open Access | Times Cited: 33
Leiming Wang, Xi Yang, Fei Zhou, et al.
Bioengineered (2022) Vol. 13, Iss. 3, pp. 7197-7208
Open Access | Times Cited: 33
Showing 1-25 of 33 citing articles:
Circular RNAs in breast cancer diagnosis, treatment and prognosis
X. Huang, CAILU SONG, JINHUI ZHANG, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2023) Vol. 32, Iss. 2, pp. 241-249
Open Access | Times Cited: 56
X. Huang, CAILU SONG, JINHUI ZHANG, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2023) Vol. 32, Iss. 2, pp. 241-249
Open Access | Times Cited: 56
The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms
Malihe Rezaee, Fatemeh Mohammadi, Atoosa Keshavarzmotamed, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 31
Malihe Rezaee, Fatemeh Mohammadi, Atoosa Keshavarzmotamed, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 31
The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances
Ayda Baghery Saghchy Khorasani, Nasim Hafezi, Mohammad‐Javad Sanaei, et al.
Cell Biochemistry and Function (2024) Vol. 42, Iss. 3
Closed Access | Times Cited: 9
Ayda Baghery Saghchy Khorasani, Nasim Hafezi, Mohammad‐Javad Sanaei, et al.
Cell Biochemistry and Function (2024) Vol. 42, Iss. 3
Closed Access | Times Cited: 9
The emerging role of noncoding RNAs in the PI3K/AKT/mTOR signalling pathway in breast cancer
Mohammed H. Abu-Alghayth, Farhan R. Khan, Tareg M. Belali, et al.
Pathology - Research and Practice (2024) Vol. 255, pp. 155180-155180
Closed Access | Times Cited: 8
Mohammed H. Abu-Alghayth, Farhan R. Khan, Tareg M. Belali, et al.
Pathology - Research and Practice (2024) Vol. 255, pp. 155180-155180
Closed Access | Times Cited: 8
circ_0004662 contributes to colorectal cancer progression by interacting with hnRNPM
Yang Zhang, Jian Wang, Rui-Liang Quan, et al.
International Journal of Oncology (2025) Vol. 66, Iss. 2
Closed Access
Yang Zhang, Jian Wang, Rui-Liang Quan, et al.
International Journal of Oncology (2025) Vol. 66, Iss. 2
Closed Access
CircRNAs: a novel potential strategy to treat breast cancer
Pangzhou Chen, Jinhui Zhang, Song Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Pangzhou Chen, Jinhui Zhang, Song Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Emerging role and clinical applications of circular RNAs in human diseases
Subhayan Sur, Jayanta K. Pal, Shashank Shekhar, et al.
Functional & Integrative Genomics (2025) Vol. 25, Iss. 1
Closed Access
Subhayan Sur, Jayanta K. Pal, Shashank Shekhar, et al.
Functional & Integrative Genomics (2025) Vol. 25, Iss. 1
Closed Access
The roles and mechanisms of circular RNAs related to mTOR in cancers
Cao Chun-Li, Yao Wang, Xinxin Wu, et al.
Journal of Clinical Laboratory Analysis (2022) Vol. 36, Iss. 12
Open Access | Times Cited: 17
Cao Chun-Li, Yao Wang, Xinxin Wu, et al.
Journal of Clinical Laboratory Analysis (2022) Vol. 36, Iss. 12
Open Access | Times Cited: 17
CircRNA (circ)_0007823 Contributes to Triple-Negative Breast Cancer Progression and Cisplatin Resistance via the miR-182-5p/FOXO1 Pathway
Haofeng Wang, Xiaojie Wang, Weida Shen, et al.
Biochemical Genetics (2024)
Closed Access | Times Cited: 3
Haofeng Wang, Xiaojie Wang, Weida Shen, et al.
Biochemical Genetics (2024)
Closed Access | Times Cited: 3
The therapeutic potential of circular RNA in triple-negative breast cancer
Aiqi Xu, Lewei Zhu, Chengcai Yao, et al.
Cancer Drug Resistance (2024)
Open Access | Times Cited: 3
Aiqi Xu, Lewei Zhu, Chengcai Yao, et al.
Cancer Drug Resistance (2024)
Open Access | Times Cited: 3
Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review
Ehsan Mehrtabar, Amirreza Khalaji, Mojtaba Pandeh, et al.
Medical Oncology (2024) Vol. 41, Iss. 9
Closed Access | Times Cited: 3
Ehsan Mehrtabar, Amirreza Khalaji, Mojtaba Pandeh, et al.
Medical Oncology (2024) Vol. 41, Iss. 9
Closed Access | Times Cited: 3
Circular RNAs in Breast Cancer: An Update
Haolin Bao, Jiehan Li, Qihang Zhao, et al.
Biomolecules (2024) Vol. 14, Iss. 2, pp. 158-158
Open Access | Times Cited: 2
Haolin Bao, Jiehan Li, Qihang Zhao, et al.
Biomolecules (2024) Vol. 14, Iss. 2, pp. 158-158
Open Access | Times Cited: 2
The regulation of microRNAs on chemoresistance in triple-negative breast cancer: a recent update
Li-Jun Yan, Andy T. Y. Lau, Yan‐Ming Xu
Epigenomics (2024) Vol. 16, Iss. 8, pp. 571-587
Closed Access | Times Cited: 2
Li-Jun Yan, Andy T. Y. Lau, Yan‐Ming Xu
Epigenomics (2024) Vol. 16, Iss. 8, pp. 571-587
Closed Access | Times Cited: 2
Trametinib and M17, a novel small molecule inhibitor of AKT, display a synergistic antitumor effect in triple negative breast cancer cells through the AKT/mTOR and MEK/ERK pathways
Hongwei Han, Minkai Yang, Zhongling Wen, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 107981-107981
Closed Access | Times Cited: 2
Hongwei Han, Minkai Yang, Zhongling Wen, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 107981-107981
Closed Access | Times Cited: 2
circRNAs in drug resistance of breast cancer
Sema Mısır, SERAP OZER YAMAN, Nina Petrović, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2022) Vol. 30, Iss. 4, pp. 157-172
Open Access | Times Cited: 11
Sema Mısır, SERAP OZER YAMAN, Nina Petrović, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2022) Vol. 30, Iss. 4, pp. 157-172
Open Access | Times Cited: 11
Dual effects of circRNA in thyroid and breast cancer
Rina Guo, Rui Zhang
Clinical & Translational Oncology (2023) Vol. 25, Iss. 12, pp. 3321-3331
Closed Access | Times Cited: 6
Rina Guo, Rui Zhang
Clinical & Translational Oncology (2023) Vol. 25, Iss. 12, pp. 3321-3331
Closed Access | Times Cited: 6
Circular RNAs in the chemoresistance of triple‐negative breast cancer: A systematic review
Hongmei Wang, Xuefeng Shan, Yang Peng, et al.
Drug Development Research (2023) Vol. 84, Iss. 5, pp. 805-814
Closed Access | Times Cited: 4
Hongmei Wang, Xuefeng Shan, Yang Peng, et al.
Drug Development Research (2023) Vol. 84, Iss. 5, pp. 805-814
Closed Access | Times Cited: 4
Genomic Alterations Affecting Competitive Endogenous RNAs (ceRNAs) and Regulatory Networks (ceRNETs) with Clinical Implications in Triple-Negative Breast Cancer (TNBC)
Amal Qattan
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2624-2624
Open Access | Times Cited: 1
Amal Qattan
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2624-2624
Open Access | Times Cited: 1
DNA damage response-related ncRNAs as regulators of therapy resistance in cancer
Ziru Gao, Xinchi Luan, Xuezhe Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Ziru Gao, Xinchi Luan, Xuezhe Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
PI3K/AKT/mTOR signaling pathway modulation by circular RNAs in breast cancer progression
Mohsen Karami Fath, Ramtin Akhavan Masouleh, Negin Afifi, et al.
Pathology - Research and Practice (2022) Vol. 241, pp. 154279-154279
Closed Access | Times Cited: 7
Mohsen Karami Fath, Ramtin Akhavan Masouleh, Negin Afifi, et al.
Pathology - Research and Practice (2022) Vol. 241, pp. 154279-154279
Closed Access | Times Cited: 7
Molecular subtypes and scoring tools related to Foxo signaling pathway for assessing hepatocellular carcinoma prognosis and treatment responsiveness
Sheng Tu, Yunqing Qiu
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 3
Sheng Tu, Yunqing Qiu
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 3
Circ_UBAP2 exacerbates proliferation and metastasis of OS via targeting miR ‐665/miR ‐370‐3p/HMGA1 axis
Weiguo Ma, Yun Gao, Xiaobin Yao, et al.
Environmental Toxicology (2023) Vol. 39, Iss. 1, pp. 212-227
Open Access | Times Cited: 2
Weiguo Ma, Yun Gao, Xiaobin Yao, et al.
Environmental Toxicology (2023) Vol. 39, Iss. 1, pp. 212-227
Open Access | Times Cited: 2
Circular RNAs as novel biomarkers in triple-negative breast cancer: a systematic review
Zahra Foruzandeh, Davood Ghavi Dorabadi, Farzaneh Sadeghi, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 10, pp. 9825-9840
Closed Access | Times Cited: 4
Zahra Foruzandeh, Davood Ghavi Dorabadi, Farzaneh Sadeghi, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 10, pp. 9825-9840
Closed Access | Times Cited: 4
Circular RNAs: novel regulators of resistance to systemic treatments in breast cancer
Xiaoqiang Guo, Yuming Hua
Neoplasma (2022) Vol. 69, Iss. 05, pp. 1019-1028
Open Access | Times Cited: 4
Xiaoqiang Guo, Yuming Hua
Neoplasma (2022) Vol. 69, Iss. 05, pp. 1019-1028
Open Access | Times Cited: 4
Current evidence on circRNAs as potential theranostic markers for detecting chemoresistance in breast cancer: a systematic review and meta‑analysis
Zixin Zhu, Hui Jiang, Jingling Xie, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 4
Zixin Zhu, Hui Jiang, Jingling Xie, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 4
